{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:48:58Z","timestamp":1793911738465,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study used data from the registry of the European Society for Blood and Marrow Transplantation (EBMT). No specific funding was obtained for this analysis."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myelodysplastic syndromes (MDS) in young adults are uncommon and underrepresented in transplant cohorts. We evaluated 697 patients aged 18\u201340 years who underwent first allogeneic hematopoietic cell transplantation (allo-HCT) reported to the EBMT between 2016 and 2021. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and graft-versus-host disease (GVHD). With a median follow-up of 2.8 years, 3-year OS and PFS were 69% (95% CI, 65\u201373) and 62% (58\u201366), respectively. At 3 years, CIR and NRM were 20% (16\u201323) and 18% (15\u201321). Grade II\u2013IV acute GVHD occurred in 28% (25\u201332) by day +100, while chronic GVHD and extensive chronic GVHD occurred in 38% (34\u201342) and 18% (14\u201321) at 3 years. In multivariable analysis, very-poor cytogenetic risk was associated with inferior OS (HR 2.81, 95% CI 1.77\u20134.45). Haploidentical donors and reduced-intensity conditioning were also associated with inferior survival. Patients younger than 30 years had superior PFS, whereas outcomes with matched sibling and matched unrelated donors were comparable. These findings support the feasibility of allo-HCT in young adults with MDS and may help inform risk-adapted transplant approaches.<\/jats:p>","DOI":"10.1038\/s41409-026-03036-3","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:51:22Z","timestamp":1790790682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome in young adults: A retrospective study on behalf of the EBMT Chronic Malignancies Working Party"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-6836","authenticated-orcid":false,"given":"Antonio Martin","family":"Jimenez Jimenez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diderik-Jan","family":"Eikema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Tuffnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4136","authenticated-orcid":false,"given":"Alexander","family":"Kulagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-3895","authenticated-orcid":false,"given":"Jan","family":"Vydra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-9138","authenticated-orcid":false,"given":"Khaled","family":"Halahleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Parovichnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Rem\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-3351","authenticated-orcid":false,"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Rabitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3638-0650","authenticated-orcid":false,"given":"Raffaella","family":"Cerretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2991-3474","authenticated-orcid":false,"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6539-226X","authenticated-orcid":false,"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-6264","authenticated-orcid":false,"given":"Joanna","family":"Drozd-Sokolowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8258-354X","authenticated-orcid":false,"given":"Kavita","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-9876","authenticated-orcid":false,"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-091X","authenticated-orcid":false,"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Chronic Malignancies Working Party of the EBMT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"3036_CR1","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1200\/JCO.2006.07.5598","volume":"24","author":"A Kuendgen","year":"2006","unstructured":"Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, et al. Myelodysplastic Syndromes in Patients Younger Than Age 50. J Clin Oncol. 2006;24:5358\u201365.","journal-title":"J Clin Oncol"},{"key":"3036_CR2","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/j.1365-2141.2007.06958.x","volume":"140","author":"C M Niemeyer","year":"2008","unstructured":"Niemeyer C M, Kratz C P. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol. 2008;140:610\u201324.","journal-title":"Br J Haematol"},{"key":"3036_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","volume":"34","author":"A M Zeidan","year":"2019","unstructured":"Zeidan A M, Shallis R M, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1\u201315.","journal-title":"Blood Rev"},{"key":"3036_CR4","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","volume":"30","author":"R Bejar","year":"2012","unstructured":"Bejar R, Stevenson K E, Caughey B A, Abdel-Wahab O, Steensma D P, Galili N, et al. Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes. J Clin Oncol. 2012;30:3376\u201382.","journal-title":"J Clin Oncol"},{"key":"3036_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"D A Arber","year":"2022","unstructured":"Arber D A, Orazi A, Hasserjian R P, Borowitz M J, Calvo K R, Kvasnicka H -M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"3036_CR6","doi-asserted-by":"publisher","first-page":"e994","DOI":"10.1016\/S2352-3026(23)00265-X","volume":"10","author":"C Gurnari","year":"2023","unstructured":"Gurnari C, Robin M, Godley L A, Drozd-Soko\u0142owska J, W\u0142odarski M W, Raj K, et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023;10:e994\u2013e1005.","journal-title":"Lancet Haematol"},{"key":"3036_CR7","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","volume":"129","author":"T De Witte","year":"2017","unstructured":"De Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753\u201362.","journal-title":"Blood"},{"key":"3036_CR8","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3390\/cancers13071610","volume":"13","author":"J P Bewersdorf","year":"2021","unstructured":"Bewersdorf J P, Zeidan A M. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Cancers. 2021;13:1610.","journal-title":"Cancers"},{"key":"3036_CR9","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Myelodysplastic Syndromes. Plymouth Meeting, PA: National Comprehensive Cancer Network."},{"key":"3036_CR10","first-page":"71","volume":"29","author":"Z DeFilipp","year":"2023","unstructured":"DeFilipp Z, Ciurea S O, Cutler C, Robin M, Warlick E D, Nakamura R, et al. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transpl Cell Ther. 2023;29:71\u201381.","journal-title":"Transpl Cell Ther"},{"key":"3036_CR11","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1182\/blood.2024025131","volume":"145","author":"C Gurnari","year":"2025","unstructured":"Gurnari C, Robin M, Ad\u00e8s L, Aljurf M, Almeida A, Barroso Duarte F, et al. Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT. Blood. 2025;145:1987\u20132001.","journal-title":"Blood"},{"key":"3036_CR12","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1038\/s41409-021-01324-8","volume":"56","author":"Y Shimomura","year":"2021","unstructured":"Shimomura Y, Hara M, Konuma T, Itonaga H, Doki N, Ozawa Y, et al. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. Bone Marrow Transpl. 2021;56:2510\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"3036_CR13","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1200\/JCO.23.02175","volume":"42","author":"C A Tentori","year":"2024","unstructured":"Tentori C A, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, et al. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes. J Clin Oncol. 2024;42:2873\u201386.","journal-title":"J Clin Oncol"},{"key":"3036_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/bmt.2016.266","volume":"52","author":"M Robin","year":"2017","unstructured":"Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, et al. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transpl. 2017;52:209\u201315.","journal-title":"Bone Marrow Transpl"},{"key":"3036_CR15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3324\/haematol.2016.159772","volume":"102","author":"C M Hirsch","year":"2017","unstructured":"Hirsch C M, Przychodzen B P, Radivoyevitch T, Patel B, Thota S, Clemente M J, et al. Molecular features of early onset adult myelodysplastic syndrome. Haematologica. 2017;102:1028\u201334.","journal-title":"Haematologica"},{"key":"3036_CR16","doi-asserted-by":"publisher","first-page":"e57392","DOI":"10.1371\/journal.pone.0057392","volume":"8","author":"X Li","year":"2013","unstructured":"Li X, Xiao Z, Chang C, Xu F, Wu L, He Q, et al. Distinct Clinical and Experimental Characteristics in the Patients Younger than 60 Years Old with Myelodysplastic Syndromes. PLoS ONE. 2013;8:e57392.","journal-title":"PLoS ONE"},{"key":"3036_CR17","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","volume":"123","author":"M G Della Porta","year":"2014","unstructured":"Della Porta M G, Alessandrino E P, Bacigalupo A, Van Lint M T, Malcovati L, Pascutto C, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014;123:2333\u201342.","journal-title":"Blood"},{"key":"3036_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjh.17817","volume":"195","author":"A Shimoni","year":"2021","unstructured":"Shimoni A, Robin M, Iacobelli S, Beelen D, Mufti G J, Ciceri F, et al. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. Br J Haematol. 2021;195:417\u201328.","journal-title":"Br J Haematol"},{"key":"3036_CR19","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2015.65.0515","volume":"34","author":"B C Shaffer","year":"2016","unstructured":"Shaffer B C, Ahn K W, Hu Z -H, Nishihori T, Malone A K, Valc\u00e1rcel D, et al. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. J Clin Oncol. 2016;34:1864\u201371.","journal-title":"J Clin Oncol"},{"key":"3036_CR20","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1097\/TP.0000000000000649","volume":"99","author":"J Gauthier","year":"2015","unstructured":"Gauthier J, Damaj G, Langlois C, Robin M, Michallet M, Chevallier P, et al. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy. Transplantation. 2015;99:1672\u201380.","journal-title":"Transplantation"},{"key":"3036_CR21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3324\/haematol.2014.116715","volume":"100","author":"C Koenecke","year":"2015","unstructured":"Koenecke C, G\u00f6hring G, de Wreede L C, van Biezen A, Scheid C, Volin L, et al. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. Haematologica. 2015;100:400\u20138.","journal-title":"Haematologica"},{"key":"3036_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/bjh.19139","volume":"204","author":"Y Shimomura","year":"2024","unstructured":"Shimomura Y, Komukai S, Kitamura T, Tachibana T, Kurosawa S, Itonaga H, et al. The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2024;204:612\u201322.","journal-title":"Br J Haematol"},{"key":"3036_CR23","doi-asserted-by":"publisher","first-page":"e705","DOI":"10.1016\/S2352-3026(25)00172-3","volume":"12","author":"M Robin","year":"2025","unstructured":"Robin M, D\u2019Aveni M, Stamatoullas A, Raffoux E, Chevallier P, Garnier A, et al. Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2025;12:e705\u2013e716.","journal-title":"Lancet Haematol"},{"key":"3036_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.801632","volume":"9","author":"S Kungwankiattichai","year":"2022","unstructured":"Kungwankiattichai S, Ponvilawan B, Roy C, Tunsing P, Kuchenbauer F, Owattanapanich W. Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis. Front Med. 2022;9:801632.","journal-title":"Front Med"},{"key":"3036_CR25","first-page":"483.e1","volume":"27","author":"B L Scott","year":"2021","unstructured":"Scott B L, Pasquini M C, Fei M, Fraser R, Wu J, Devine S M, et al. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes\u2014Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transpl Cell Ther. 2021;27:483.e1\u2013483.e6.","journal-title":"Transpl Cell Ther"},{"key":"3036_CR26","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"B L Scott","year":"2017","unstructured":"Scott B L, Pasquini M C, Logan B R, Wu J, Devine S M, Porter D L, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017;35:1154\u201361.","journal-title":"J Clin Oncol"},{"key":"3036_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00729-y","volume":"12","author":"K Raj","year":"2022","unstructured":"Raj K, Eikema D -J, Sheth V, Koster L, de Wreede L C, Blaise D, et al. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT. Blood Cancer J. 2022;12:140.","journal-title":"Blood Cancer J"},{"key":"3036_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/bloodadvances.2025017194","volume":"10","author":"D Modi","year":"2026","unstructured":"Modi D, Aljawai Y M, DeFor T E, Bupp C, Al Malki M M, Bola\u00f1os-Meade J, et al. Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide. Blood Adv. 2026;10:233\u201345.","journal-title":"Blood Adv"},{"key":"3036_CR29","first-page":"316.e1","volume":"30","author":"Y Nakaya","year":"2024","unstructured":"Nakaya Y, Koh H, Konuma T, Shimomura Y, Ishiyama K, Itonaga H, et al. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome. Transpl Cell Ther. 2024;30:316.e1\u2013316.e12.","journal-title":"Transpl Cell Ther"},{"key":"3036_CR30","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.24.00184","volume":"42","author":"B C Shaffer","year":"2024","unstructured":"Shaffer B C, Gooptu M, DeFor T E, Maiers M, Bola\u00f1os-Meade J, Abboud R, et al. Post-Transplant Cyclophosphamide\u2013Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors. J Clin Oncol. 2024;42:3277\u201386.","journal-title":"J Clin Oncol"},{"key":"3036_CR31","first-page":"346.e1","volume":"29","author":"J J Auletta","year":"2023","unstructured":"Auletta J J, Kou J, Chen M, Bolon Y -T, Broglie L, Bupp C, et al. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Transpl Cell Ther. 2023;29:346.e1\u2013346.e10.","journal-title":"Transpl Cell Ther"},{"key":"3036_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","volume":"104","author":"C S Cutler","year":"2004","unstructured":"Cutler C S. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579\u201385.","journal-title":"Blood"},{"key":"3036_CR33","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1182\/blood.2023020079","volume":"142","author":"E S Hellstr\u00f6m-Lindberg","year":"2023","unstructured":"Hellstr\u00f6m-Lindberg E S, Kr\u00f6ger N. Clinical decision-making and treatment of myelodysplastic syndromes. Blood. 2023;142:2268\u201381.","journal-title":"Blood"},{"key":"3036_CR34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bjh.18822","volume":"202","author":"A Jandin","year":"2023","unstructured":"Jandin A, Pochon C, Campidelli A, D\u2019Aveni M, Kicki C, Notarantonio AB, et al. Age-related immune cell dynamics influence outcomes after allogeneic haematopoietic cell transplantation. Br J Haematol. 2023;202:122\u201334.","journal-title":"Br J Haematol"},{"key":"3036_CR35","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/ijms17060838","volume":"17","author":"S Bannon","year":"2016","unstructured":"Bannon S, DiNardo C. Hereditary Predispositions to Myelodysplastic Syndrome. Int J Mol Sci. 2016;17:838.","journal-title":"Int J Mol Sci"},{"key":"3036_CR36","first-page":"973","volume":"31","author":"A M Jimenez Jimenez","year":"2025","unstructured":"Jimenez Jimenez A M, Spellman S R, Politikos I, McCurdy S R, Devine S M, Al Malki M M, et al. Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP\/CIBMTR. Transpl Cell Ther. 2025;31:973\u201388.","journal-title":"Transpl Cell Ther"},{"key":"3036_CR37","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41375-025-02814-0","volume":"40","author":"C Gurnari","year":"2026","unstructured":"Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, et al. DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study. Leukemia. 2026;40:178\u201387.","journal-title":"Leukemia"},{"key":"3036_CR38","doi-asserted-by":"crossref","unstructured":"Greinix HT, Eikema D-J, Koster L, Penack O, Yakoub-Agha I, Montoto S, et al. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica 2022;107:1054-63.","DOI":"10.3324\/haematol.2020.265769"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03036-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03036-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03036-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:51:24Z","timestamp":1790790684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03036-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":38,"alternative-id":["3036"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03036-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"16 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}